Demir Filiz Topaloğlu, Altun Ece
Faculty of Medicine, Department of Dermatological and Venereal Diseases, Istanbul Medipol University, Istanbul, Turkey.
J Cosmet Dermatol. 2024 Dec;23(12):3911-3917. doi: 10.1111/jocd.16540. Epub 2024 Aug 23.
Photoactivation has been suggested to enhance the efficacy of platelet-rich plasma (PRP) in conditions other than dermatological diseases.
To evaluate the efficacy of photoactivated PRP (P-PRP) treatment for melasma by comparing it with non-photoactivated, classical PRP (C-PRP).
The study consisted of 38 female patients diagnosed with melasma between April 2022 and May 2023. The patients were randomized into the P-PRP and C-PRP groups. Three sessions of P-PRP or C-PRP were applied to the patients at 2-week intervals. The Melasma Area and Severity Index (MASI) and Melasma Quality of Life Index (MELASQoL) scores were compared before and 2 weeks after treatment.
The median age was 38 years, and the median disease duration was 60 months. Clinically, 94.7% of the cases were centrofacial and 5.3% were malar. According to Wood's lamp examination, 55.3% of the cases were epidermal, 13.2% were dermal, and 31.6% were mixed-type. The median pre- and post-treatment scores were 14.5 and 9, respectively, for MASI and 36.5 and 17, respectively, for MELASQoL. The post-treatment MASI and MELASQoL scores of both groups significantly decreased (p < 0.001 for both). However, the intergroup difference was not significant. When all patients were evaluated together a moderate, positive, and significant relationship was detected between PRP and the pre- and post-treatment MASI and MELASQoL scores (r = 0.494 and p = 0.002). No side effects associated with PRP were observed.
PRP is an effective and safe treatment method for melasma. Further studies are needed to evaluate the contribution of photoactivation to PRP treatment in melasma.
光活化已被认为可增强富血小板血浆（PRP）在皮肤病以外疾病中的疗效。
通过将光活化PRP（P-PRP）治疗与未光活化的传统PRP（C-PRP）进行比较，评估其治疗黄褐斑的疗效。
该研究纳入了2022年4月至2023年5月期间诊断为黄褐斑的38名女性患者。患者被随机分为P-PRP组和C-PRP组。每隔2周对患者进行3次P-PRP或C-PRP治疗。比较治疗前和治疗后2周的黄褐斑面积和严重程度指数（MASI）以及黄褐斑生活质量指数（MELASQoL）评分。
中位年龄为38岁，中位病程为60个月。临床上，94.7%的病例为面部中央型，5.3%为颧部型。根据伍德灯检查，55.3%的病例为表皮型，13.2%为真皮型，31.6%为混合型。MASI的治疗前和治疗后中位评分分别为14.5和9，MELASQoL的治疗前和治疗后中位评分分别为36.5和17。两组的治疗后MASI和MELASQoL评分均显著降低（两者p均<0.001）。然而，组间差异不显著。当对所有患者进行综合评估时，发现PRP与治疗前和治疗后的MASI以及MELASQoL评分之间存在中度、正性且显著的相关性（r = 0.494，p = 0.002）。未观察到与PRP相关的副作用。
PRP是治疗黄褐斑的一种有效且安全的治疗方法。需要进一步研究来评估光活化对PRP治疗黄褐斑的贡献。
